Argenx Se (ARGX) Intangibles (2015 - 2026)
Argenx Se's (ARGX) quarterly Intangibles came in at $266.0 million in Q2 2026, down 99.88% YoY from $219.0 billion in Q2 2025, and down 2.21% on a QoQ basis from $272.0 million in Q4 2025.
Argenx Se (ARGX) Intangibles (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has 12 years of Intangibles data on file, last reported at $266.0 million in Q2 2026.
- Quarterly Intangibles fell 99.88% year-over-year to $266.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $266.0 million (down 99.88% YoY) and the FY2025 annual result came in at $7.3 billion, up 23.1% from the prior year.
- Intangibles eased to $266.0 million in Q2 2026, from $272.0 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $219.0 billion in Q2 2025 to a low of $125.2 million in Q4 2023.
- A 5-year average of $24.5 billion and a median of $181.4 million in 2024 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2025 — Intangibles jumped 154354.98% — and 2026, when it tumbled 99.88%.
- Tracing ARGX's Intangibles over 5 years: stood at $176.5 million in 2022, then slipped by 29.06% to $125.2 million in 2023, then surged by 44.89% to $181.4 million in 2024, then jumped by 49.91% to $272.0 million in 2025, then slipped by 2.21% to $266.0 million in 2026.
- The last three Intangibles figures came in at $266.0 million (Q2 2026), $272.0 million (Q4 2025), and $219.0 billion (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 266.00 Mn |
| Dec 31, 2025 | 272.00 Mn |
| Jun 30, 2025 | 218.98 Bn |
| Dec 31, 2024 | 181.45 Mn |
| Jun 30, 2024 | 141.77 Mn |
| Dec 31, 2023 | 125.23 Mn |
| Jun 30, 2023 | 189.86 Mn |
| Dec 31, 2022 | 176.52 Mn |
| Jun 30, 2022 | 171.29 Mn |
| Dec 31, 2021 | 171.68 Mn |
| Jun 30, 2021 | 175.17 Mn |
| Dec 31, 2020 | 162.64 Mn |
| Jun 30, 2020 | 45.10 Mn |
| Dec 31, 2019 | 44.45 Mn |
| Jun 30, 2019 | 39.86 Mn |
| Dec 31, 2018 | 63,918.20 |
| Jun 30, 2018 | 9,547.56 |
| Dec 31, 2017 | 116,565.82 |
| Jun 30, 2017 | 13,194.59 |
| Dec 31, 2016 | 18,355.31 |